Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down to $15.41

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) gapped down prior to trading on Friday . The stock had previously closed at $15.41, but opened at $14.95. Gyre Therapeutics shares last traded at $15.22, with a volume of 5,521 shares trading hands.

Gyre Therapeutics Stock Performance

The stock’s 50-day moving average is $17.39. The company has a market cap of $1.32 billion, a PE ratio of -0.75 and a beta of 2.11.

Institutional Trading of Gyre Therapeutics

An institutional investor recently bought a new position in Gyre Therapeutics stock. Northern Trust Corp bought a new stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,614 shares of the company’s stock, valued at approximately $632,000. Northern Trust Corp owned approximately 0.97% of Gyre Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.